Search filters
Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 90
  • 14
  • 168
  • 694
  • 444
  • 14
  • 31
  • 1
  • 4
  • 646

Found 696 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT (LESS-VT) Study

99 years or below
All genders
Please see section1 of the full protocol
Learn More

Evaluation of QDOT MICRO catheter for pulmonary vein isolation (PVI) in subjects with Paroxysmal Atrial Fibrillation (PAF)

18 years - 99 years
All genders
The purpose of this study is to demonstrate the safety and 12-Month effectiveness of the QDOT MICRO catheter when used with the nMARQ RF generator in the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (PAF) during standard electrophysiology mapping and RF ablation procedures.
Learn More

The Role of the Microbiome in Inter-Individual Variability in NSAID Disposition and Response

18 years - 99 years
All genders
Phase 1
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. Mounting evidence indicates that rectal administration of NSAIDs is also effective in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) by an unknown mechanism. Alterations in the salivary and fecal microbiome have been observed in patients with …
Learn More

Phase II Study to Assess the Safety Tolerability and Target Engagement of AMX0035 a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimers Disease

55 years - 89 years
All genders
Phase 2
This is a double blind, randomized, placebo controlled trial in subjects with mild cognitive impairment or dementia due to Alzheimer's disease (AD). AMX0035 is a combination of two compounds, Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA) that are hypothesized to prevent neuronal death through distinct pathways. AMX0035 is not approved …
Learn More

Psoriasis Specimen BioBank

18 years - 99 years
All genders
The last 2 decades have witnessed a dramatic expansion in our understanding of the genetics, pathophysiology, and comorbidities of psoriasis leading to the development and approval of a variety of treatment strategies targeting pathways such as JAK/STAT, PDE4, TNF, IL12/23, and IL-17. We propose creating a biobank of specimens from …
Learn More

A Phase 3 Randomized Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza)

99 years or below
All genders
Phase 3
This is a randomized, double-blind, placebo-controlled, multicenter study in patients with primary cold agglutinin disease (CAgD) without a recent history of blood transfusion. Eligible patients will receive study drug (BIVV009 or placebo) and undergo safety and efficacy assessments for 6 months (26 weeks) during Part A. Following completion of the …
Learn More

A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

99 years or below
All genders
Phase 3
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
Learn More

UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma

99 years or below
All genders
Phase 2
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
Learn More

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

99 years or below
All genders
Phase 2
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
Learn More

mPeer2Peer

99 years or below
All genders
The purpose of this study is to develop and test the utility of a smartphone program, mPhenomic, that facilitates peer recruitment via SMS text messages and assess how different behavioral incentives affect this system. Outcomes are measured by the number of referrals that participants, called seeds, make to people, named …
Learn More
171 - 180 of 696